TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06440005: A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

Sponsor: Angiex, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 80 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,445,136

Rescue Site Savings

+$942,480

Unlock Full NCT06440005 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06440005 Rescue Dossier →